Cargando…

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy

PURPOSE: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). METHODS: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Sumit Randhir, Sahoo, Niroj Kumar, Goud, Nallamasa Rohit, Chhablani, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611246/ https://www.ncbi.nlm.nih.gov/pubmed/31238423 http://dx.doi.org/10.4103/ijo.IJO_638_18

Ejemplares similares

Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy – short term study
por: Mishra, Sai B., et al.
Publicado: (2022)

Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2014)

Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2013)

One year outcomes of eyes with polypoidal choroidal vasculopathy with ≥20/40 visual acuity treated with anti-vascular endothelial growth factor agents
por: Singh, Sumit R., et al.
Publicado: (2022)

Treatment of polypoidal choroidal vasculopathy with intravitreal bevacizumab monotherapy
por: Tan, Colin S H, et al.
Publicado: (2013)

Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection
por: Singh, Sumit Randhir, et al.
Publicado: (2018)

Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
por: Mansour, Ahmad M., et al.
Publicado: (2020)

Pachydrusen in polypoidal choroidal vasculopathy in an Indian cohort
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion
por: Braimah, Imoro Z, et al.
Publicado: (2019)

Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy
por: Anshuman, Kumar, et al.
Publicado: (2019)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
por: Lee, Sang Eun, et al.
Publicado: (2019)

Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
por: Arakawa, Akira, et al.
Publicado: (2017)

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
por: Miyakubo, Tomoko, et al.
Publicado: (2023)

Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year
por: Singh, Sumit Randhir, et al.
Publicado: (2020)

Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy
por: Asano, Shotaro, et al.
Publicado: (2018)

Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept
por: Xue, Yin, et al.
Publicado: (2022)

Polypoidal choroidal vasculopathy in a case of retinitis pigmentosa, successfully treated with intravitreal aflibercept
por: Takahashi, Nana, et al.
Publicado: (2021)

Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2020)

Intravitreal Ziv-Aflibercept in Treatment of Naïve Chronic Central Serous Chorioretinopathy Related Choroidal Neovascular Membrane
por: Radke, Nishant, et al.
Publicado: (2017)

Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases
por: HodjatJalali, Kamran, et al.
Publicado: (2017)

One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
por: Weng, Hsin-Yu, et al.
Publicado: (2019)

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
por: Tamachi, Tomoko, et al.
Publicado: (2020)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016)

Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy
por: Vyas, Chinmayi Himanshuroy, et al.
Publicado: (2021)

Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: Short-term results
por: Mitamura, Yoshinori, et al.
Publicado: (2010)

Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy
por: Kitahashi, Masayasu, et al.
Publicado: (2014)

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Chhablani, Jay
Publicado: (2015)

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita, Mariko, et al.
Publicado: (2014)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy
por: Peng, Yuting, et al.
Publicado: (2018)

Disadvantages of photodynamic therapy for polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar
Publicado: (2010)

Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy
por: Cho, Han Joo, et al.
Publicado: (2012)

Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy
por: Yap, Aaron, et al.
Publicado: (2022)

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
por: Wong, James G., et al.
Publicado: (2017)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy
por: Lee, Sun Young, et al.
Publicado: (2008)

Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013)

One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
por: Choo, Hun Gu, et al.
Publicado: (2021)

Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
por: Ma, I-Hsin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tjf0m436dl8f2fg7m8to0758ju